Literature DB >> 21738111

Bone metastases, general and clinical issues.

C Greco1, L Forte, P Erba, G Mariani.   

Abstract

The skeleton is the most common organ for metastasis from solid tumours. Bone metastases pose significant diagnostic and clinical challenges and represent an important cause of cancer-related morbidity. Without appropriate bone-directed therapy, many patients will be at high risk for potentially debilitating skeletal-related events (SREs), such as pain, bone fractures, neurologic deficits and hypercalcemia, severely impacting on the patient's quality of life. Because of their high incidence, bone metastases impose significant demands on health care resources. The optimal management of skeletal metastases depends on the underlying biology of the disease, the extent of bone involvement, the presence and severity of symptoms, the availability of effective systemic therapies and life expectancy of the patient. This article discusses clinical issues concerning diagnosis and available treatment approaches based on the presentation of skeletal involvement. Emphasis is placed on the role of external beam-radiotherapy as a local mode of treatment for palliation of bone pain, decompression of epidural compression and as potential ablative approach through high-dose image-guided irradiation (IGRT) in patients presenting with oligometastatic disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21738111

Source DB:  PubMed          Journal:  Q J Nucl Med Mol Imaging        ISSN: 1824-4785            Impact factor:   2.346


  6 in total

Review 1.  Radiopharmaceuticals for metastatic bone pain palliation: available options in the clinical domain and their comparisons.

Authors:  Tapas Das; Sharmila Banerjee
Journal:  Clin Exp Metastasis       Date:  2016-12-17       Impact factor: 5.150

Review 2.  Spinal metastases: From conventional fractionated radiotherapy to single-dose SBRT.

Authors:  Carlo Greco; Oriol Pares; Nuno Pimentel; Elizabeth Moser; Vasco Louro; Xavier Morales; Barbara Salas; Zvi Fuks
Journal:  Rep Pract Oncol Radiother       Date:  2015-04-18

3.  Effects of low-dose capecitabine on Samarium-153-EDTMP therapy for painful bone metastases.

Authors:  Sukanta Barai; Sanjay Gambhir; Neeraj Rastogi; Anil Mandani; Murthy Siddegowda
Journal:  Indian J Nucl Med       Date:  2015 Apr-Jun

4.  PET Tracer 18F-Fluciclovine Can Detect Histologically Proven Bone Metastatic Lesions: A Preclinical Study in Rat Osteolytic and Osteoblastic Bone Metastasis Models.

Authors:  Shuntaro Oka; Masaru Kanagawa; Yoshihiro Doi; David M Schuster; Mark M Goodman; Hirokatsu Yoshimura
Journal:  Theranostics       Date:  2017-05-15       Impact factor: 11.556

5.  Clinical utility of 188Rhenium-hydroxyethylidene-1,1-diphosphonate as a bone pain palliative in multiple malignancies.

Authors:  Ajit S Shinto; Madhava B Mallia; Mythili Kameswaran; K K Kamaleshwaran; Jephy Joseph; E R Radhakrishnan; Indira V Upadhyay; R Subramaniam; Madhu Sairam; Sharmila Banerjee; Ashutosh Dash
Journal:  World J Nucl Med       Date:  2018 Oct-Dec

6.  RNF219/α-Catenin/LGALS3 Axis Promotes Hepatocellular Carcinoma Bone Metastasis and Associated Skeletal Complications.

Authors:  Shuxia Zhang; Yingru Xu; Chan Xie; Liangliang Ren; Geyan Wu; Meisongzhu Yang; Xingui Wu; Miaoling Tang; Yameng Hu; Ziwen Li; Ruyuan Yu; Xinyi Liao; Shuang Mo; Jueheng Wu; Mengfeng Li; Erwei Song; Yanfei Qi; Libing Song; Jun Li
Journal:  Adv Sci (Weinh)       Date:  2020-12-31       Impact factor: 16.806

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.